Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- ado-trastuzumab emtansine
- Biaxin (clarithromycin)
Interactions between your drugs
clarithromycin ado-trastuzumab emtansine
Applies to: Biaxin (clarithromycin), ado-trastuzumab emtansine
Clarithromycin may increase the blood levels of ado-trastuzumab emtansine. This can increase the risk and/or severity of side effects such as liver impairment, heart failure, nerve damage, and bleeding problems. You may not be able to take ado-trastuzumab emtansine during treatment with clarithromycin, or you may need a dose adjustment and/or more frequent monitoring by your doctor to safely use both medications. Your doctor may also be able to prescribe alternatives that do not interact. You should contact your doctor if you experience shortness of breath, coughing, swelling of the legs or ankles, sudden weight gain, palpitations, dizziness or loss of consciousness, as these may be early symptoms of heart failure. You should also seek immediate medical attention if you develop signs and symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
clarithromycin food
Applies to: Biaxin (clarithromycin)
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.